-
Ximelagatran
- indication:For the treatment of acute deep vein thrombosis.
- pharmacologypharmacology:
- mechanism: Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. It acts solely by inhibiting the actions of thrombin. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran.
- toxicity: Hepatotoxicity (liver damage) was reported during trials.
- absorprion: Rapidly absorbed by the small intestine with an oral bioavailability of 20%.
- halflife: 3-5 hours
- roouteelimination:
- volumedistribution:
- clearance: